MorphoSys AG reported an increase in revenue and a smaller operating loss in 2022 as it tightened its focus on cancer. The German company is completing development of pelabresib, a product for myelofibrosis, and growing sales of its marketed antibody therapeutic, Monjuvi (tafasitamab) for diffuse large B-cell lymphoma.
